The frequency of polyneuropathy and comparison of laboratory parameters in patients with multiple myeloma

Year 2015, Volume: 42 Issue: 4, 445 - 448, 08.01.2016

Abdullah Sakin Mesut Ayer Kenan Çelik Fatih Berkil Hürtan Acar Aylin Ayer Ayşegül Sakin Fuat Şar

Abstract

Objective: Multiple myeloma(MM) is a B-cell neoplasia, characterized by clonal expansion of malignant plasma cells in bone marrow. Polyneuropathy (PN) is the most important complications in the treatment of MM. The aim of our study is to find out whether the lab parameters and the incidence of PN, are markers in MM patients or not.

Methods: Totally 70 patients (31 male, 39 female) who presented to hematology outpatient department were retrospectively evaluated. Pre-treatment laboratory parameters and electromyography records of the patients taken from the file.

Results: 15.7% of the cases the diagnosis was immediately available PN. Levels of β2 microglubin, uric acid, total protein, calcium, ALT, AST, creatinine, LDH and albumin levels didn’t differ significantly between two groups (p>0.05).

Conclusion: Presence or development of PN in MM and its readiness to be used as an early marker, will obviously facilitate the treatment and follow-up of MM.

Key words: Multiple myeloma, polyneuropathy, electromyography

Keywords

Multipl miyelom, polinöropati, elektromiyografi

References

• Decaux O, Laurat E, Perlat A, et al. Systemic manifestations of monoclonal gammopathy. Eur J Intern Med 2009;20:457-461.
• Ramchandren S, Lewis RA. Monoclonal gammopathy and
• neuropathy. Curr Opin Neurol 2009;22:480-485.
• Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012;26:595-608.
• Holland J, Trenkner DA, Wasserman TH, Fineberg B. Plasmacytoma. Treatment results and conversion to myeloma.
• Cancer 1992;69:1513-1517.
• Jemal A, Murray T, Samuels A, et al. Cancer Statistics. CA
• Cancer J Clin 2003;53:5-26.
• Antoine JC, Camdessanché JP. Peripheral nervous system
• involvement in patients with cancer. Lancet Neurol 2007;6:75-86.
• Denier C, Lozeron P, Adams D, et al. Multifocal neuropathy due to plasma cell infiltration of peripheral nerves in multiple myeloma. Neurology. 2006;66:917-918.
• A. Sakin ve ark. Multipl myelomlu hastalarda polinöropati sıklığı
• Dicle Tıp Derg / Dicle Med J www.diclemedj.org Cilt / Vol 42, No 4, 445-448
• Nobile-Orazio E. Neuropathy and monoclonal gammopathy.
• Handb Clin Neurol 2013;115:443-459.
• Silberman J, Lonial S. Review of peripheral neuropathy in plasma cell disorders. Hematol Oncol 2008;26:55-65.
• Kelly JJ, Kyle RA, O’Brien PC, Kohn J. Prevalence of monoclonal proteins in peripheral neuropathy. Neurology 1981; 31: 1480-1483.
• Reddy GK, Mughal TI, Lonial S. Optimizing the management
• of treatment-related peripheral neuropathy in patients with multiple myeloma. Support Cancer Ther 2006;4:19-22.
• Ramchandren S, Lewis RA. Monoclonal gammopathy and
• neuropathy. Curr Opin Neurol 2009;22:480-485.